問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Endocrinology

Division of General Internal Medicine

Division of Cardiovascular Diseases

Taichung Veterans General Hospital (在職)

Division of Cardiovascular Diseases

更新時間：2024-06-04

宋思賢Sung, Shih-Hsien
  • Principal Investigator
  • Clinical Trial Experience (year) 13 years 1 個月

Recruiting Trial

54Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

宋思賢

List

117Cases

2025-03-01 - 2032-12-31

Phase II

Active
An Open-label Extension Study to Evaluate Safety and Tolerability of Sotatercept (MK-7962) Administered Using a Weight-banded Approach in Participants With Pulmonary Arterial Hypertension (PAH) on Standard of Care

  • Condition/Disease

    Pulmonary Arterial Hypertension

  • Test Drug

    Freeze-dried injection

Participate Sites
3Sites

Recruiting3Sites

2025-11-14 - 2031-03-30

Active
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

  • Condition/Disease

    Heart Failure With Preserved Ejection Fraction

  • Test Drug

    subcutaneous injection

Participate Sites
6Sites

Not yet recruiting6Sites

2024-09-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting16Sites

2020-05-08 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2019-08-30 - 2024-12-17

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2020-07-01 - 2023-11-01

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2026-06-01 - 2030-06-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Recruiting14Sites

2025-06-01 - 2027-12-31

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2025-07-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-03-01 - 2030-06-30

Active

  • Condition/Disease

  • Test Drug

Participate Sites
18Sites

Recruiting18Sites

1 2 3 4 5 12
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB